Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Revenue (2019 - 2023)

Revolution Medicines has reported Revenue over the past 5 years, most recently at $742000.0 for Q4 2023.

  • For Q4 2023, Revenue fell 95.16% year-over-year to $742000.0; the TTM value through Sep 2024 reached $742000.0, down 97.16%, while the annual FY2023 figure was $11.6 million, 67.27% down from the prior year.
  • Revenue for Q4 2023 was $742000.0 at Revolution Medicines, down from $3.8 million in the prior quarter.
  • Over five years, Revenue peaked at $15.3 million in Q4 2022 and troughed at $742000.0 in Q4 2023.
  • A 5-year average of $8.9 million and a median of $9.5 million in 2021 define the central range for Revenue.
  • Biggest five-year swings in Revenue: soared 204.81% in 2022 and later plummeted 95.16% in 2023.
  • Year by year, Revenue stood at $12.1 million in 2019, then fell by 27.61% to $8.8 million in 2020, then grew by 8.1% to $9.5 million in 2021, then surged by 62.05% to $15.3 million in 2022, then plummeted by 95.16% to $742000.0 in 2023.
  • Business Quant data shows Revenue for RVMD at $742000.0 in Q4 2023, $3.8 million in Q2 2023, and $7.0 million in Q1 2023.